COVID-2019 vaccine - Liaoning Maokangyuan Biotech/Zhongyi Anke Biotechology
Alternative Names: Recombinant SARS-CoV-2 Vaccine; Recombinant SARS-CoV-2 Vaccine (CHO Cell); SARS-CoV-2 vaccine (CHO Cell)Latest Information Update: 31 Oct 2021
At a glance
- Originator Liaoning Maokangyuan Biotech; Zhongyi Anke Biotechology
- Developer Academy of Military Medical Sciences; Jiangsu Provincial Center for Disease Control and Prevention; Liaoning Maokangyuan Biotech; Zhongyi Anke Biotechology
- Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 23 Mar 2021 Phase-II clinical trials in COVID-2019 infections (In the elderly, Prevention, In adults) in China (IM) (NCT04813562)
- 30 Oct 2020 Phase-I clinical trials in COVID-2019 infections (Prevention, In adults, In the elderly) in China (IM) (NCT04636333)